vrpx stock: Virpax Pharmaceuticals Overview

VRPX (Virpax Pharmaceuticals, Inc.) — stock

vrpx stock refers to the ticker VRPX for Virpax Pharmaceuticals, Inc., a U.S.-based preclinical-stage biopharmaceutical company focused on non-opioid pain-management drug-delivery technologies. This article explains who Virpax is, what its lead programs are, the company’s listing and compliance history, its public filings and financial posture, and key risks that investors should consider. It also summarizes market behavior and recent material events through early April 2025.

Note: vrpx stock is a corporate equity ticker, not a cryptocurrency token or blockchain asset.

Company overview

Virpax Pharmaceuticals, Inc. (VRPX) is a small-cap, U.S.-incorporated biopharmaceutical company headquartered in Berwyn, Pennsylvania. Founded in 2016, Virpax states its mission as developing novel drug-delivery platforms to enable non-opioid pain therapies and improve central nervous system (CNS) delivery of labile peptides. The company’s research emphasizes topical, injectable liposomal, and intranasal nanotechnology delivery systems designed to extend duration of analgesia or improve brain targeting for peptide therapeutics.

As an equity, vrpx stock represents ownership in a company that, as of the most recent public filings and market reports, has no approved commercial products and operates in the preclinical / early development stage. That operational profile is central to the company’s risk and valuation profile.

History and corporate timeline

This section summarizes major corporate milestones and public filing events for Virpax as they relate to vrpx stock, based on public disclosures and market reports.

• 2016 — Company founded (corporate formation and early R&D phase focused on drug-delivery technologies).
• 20XX–2021 — Early-stage research and nonclinical program development (company disclosures describe preclinical studies and formulation development across multiple platforms).
• S-1 and registration filings — Virpax completed public registration documentation in connection with becoming a publicly traded company; SEC registration statements and S-1 amendments disclosed the company’s business model, financials and risk factors (see company SEC filings for exact filing dates and amendments).
• Listing history — vrpx stock was previously quoted on the Nasdaq exchange during earlier stages of public trading and later became quoted on the OTC marketplace after Nasdaq determined the company no longer met certain listing standards (see “Listing, compliance and delisting events” below for dates and outcomes).
• March 21, 2025 — The company executed a reverse stock split (reported in company filings and market-data services). This corporate action altered outstanding share counts and is an important factor in per-share historical price comparisons for vrpx stock.
• Early April 2025 — Nasdaq issued deficiency notices and/or determined delisting actions that affected the company’s listing status; public sources reported the company’s responses or appeals in filings and market reports.
• 2024–2025 — Company completed follow-on financings and reported registered offerings in its SEC filings; such financings influenced cash runway, shareholder dilution and share counts noted in market services.

As of the recent reporting window through April 2025, vrpx stock had experienced multiple structural changes (reverse split, listing review and financing activity) that materially affected liquidity and per-share math. For authoritative dates and legal detail, readers should consult Virpax SEC filings in EDGAR (S-1 series, 10-Qs and Form 8-Ks).

Business operations and product pipeline

Virpax’s technology strategy centers on drug-delivery platforms intended to provide non-opioid analgesia and enhance CNS delivery of peptides. Programs are generally at preclinical or early-development stages.

Epoladerm

Epoladerm is described by the company as a topical spray-film delivery candidate aimed at treating osteoarthritis pain through localized, sustained delivery of active analgesic agents. Public disclosures classify Epoladerm as a formulation-stage program with preclinical profiling completed and potential plans for further development pending funding and regulatory steps.

Probudur

Probudur is an injectable liposomal gel local anesthetic formulation developed for postoperative pain control. Virpax has reported preclinical dose-ranging and animal-model data (including swine models) that the company describes as supportive of prolonged analgesic effect compared with standard formulations. Probudur remained in preclinical development pending IND-enabling studies and potential first-in-human planning.

Envelta

Envelta is an intranasal, nanotechnology-based platform designed to deliver metabolically labile peptides to the brain by improving nasal-to-brain transport. Company materials note the technology’s intent to enable peptide therapeutics that otherwise have poor bioavailability when administered systemically.

Other candidates (AnQlar, NobrXiol, etc.)

Virpax lists additional preclinical programs, including barrier/antiviral formulations (AnQlar) and enhanced cannabinoid brain-delivery formulations (NobrXiol) among exploratory projects. These remain early-stage and are subject to the same preclinical-to-clinical transition risks as other programs.

Research, clinical and regulatory interactions

Public disclosures and investor presentations indicate Virpax’s programs have been largely preclinical, with company-reported animal-model results and dose-ranging assessments. Notable points:

• Preclinical outcomes — Virpax reported animal-model data for Probudur and other formulations that management characterized as demonstrating extended duration of analgesia in comparison to control formulations. These preclinical results are not equivalent to human efficacy and primarily serve to prioritize development candidates.
• Regulatory engagement — Company filings reference interactions with regulatory authorities in the context of preparing for IND-enabling studies. As of early 2025, no pivotal human clinical trials had been publicly announced for VRPX programs; regulatory milestones to watch are IND submissions and any FDA feedback that would permit human trials.

All clinical and regulatory status statements in investor materials should be cross-checked against SEC filings and formal company press releases for dates and specifics.

Financials and corporate filings

Virpax’s public filings (S-1 series, 10-Qs) indicate the company is pre-revenue from product sales and reports recurring net losses typical for R&D-stage biopharma.

• Revenue: Virpax has limited or no commercial revenue reported in recent periodic filings; primary funding historically came from equity financings and registered offerings.
• Net losses: Public filings report net losses associated with R&D, G&A, and preclinical activities; the company’s income statements reflect ongoing negative operating cash flows.
• Cash position and financings: Virpax conducted follow-on offerings and financing activities reported in recent SEC filings. These financings affect reported cash runway and shareholder dilution; the company’s disclosed cash and working capital balances should be consulted in the most recent 10-Q or Form 8-K for precise, dated figures.

For readers: always refer to the company’s latest 10-Q or 10-K for up-to-date, specific numbers on cash, liabilities, and capital-raising events.

Stock market information

vrpx stock has been quoted on both Nasdaq (earlier) and on the OTC Markets (following Nasdaq listing challenges). Key market characteristics observed in public market-data services include:

• Low absolute share price: The security has traded at low per-share prices typical of microcap/penny-stock equities, resulting in amplified percentage volatility.
• Market capitalization: Public summaries place the company in the microcap / small-cap range after accounting for outstanding shares and market pricing; some market pages reported market-cap figures below low tens of millions (USD) around the time of recent listing events. Readers should verify the precise market-cap number on the date of interest in market-data providers or company filings.
• Average volume and liquidity: Trading volume for vrpx stock has historically been modest, with frequent thin liquidity periods that can widen spreads and make sizable trades difficult without market impact.
• Reverse split effects: The March 21, 2025 reverse stock split changed the share count and per-share comparability; historical charts commonly show adjusted prices to account for splits, but absolute volume and outstanding-share metrics require reference to post-split filings.

Market-data platforms (MarketWatch, StockAnalysis, TipRanks, Morningstar) and brokerage quote feeds are typical sources for the most recent price, volume and market-cap updates for vrpx stock.

Listing, compliance and delisting events

Virpax’s listing history includes prior quotation on Nasdaq and subsequent quotation on the OTC market following listing standard determinations. Public-source highlights:

• Nasdaq deficiency and delisting notices — In early April 2025 Nasdaq issued a delisting determination or deficiency notices to Virpax citing noncompliance with listing standards; those actions and the company’s procedural responses were reported by market-data services and summarized in company 8-K filings.
• Company responses and appeals — Virpax filed responses or sought extensions/appeals in accordance with Nasdaq procedures as described in SEC filings and press updates. The outcome of appeals and their timing can materially affect investor liquidity and access to market venues for vrpx stock.
• OTC quotation — Following Nasdaq listing challenges and delisting actions for some reporting periods, vrpx stock has been quoted on OTC Markets, where trading and disclosure dynamics differ from national exchange listings.

Investors should consult the company’s 8-Ks, Nasdaq notices, and OTC Markets disclosures for the definitive, time-stamped record of listing and compliance matters affecting vrpx stock.

Corporate governance and management

Public disclosures list Virpax’s executive officers and board composition in S-1 registrations and periodic reports. Notable governance considerations commonly highlighted by market watchers for microcap biopharma companies include:

• Board and management changes — Company filings record any executive appointments, director resignations, and committee updates. Governance updates can affect investor perceptions of operational stability and strategic direction.
• Independence and audit matters — Nasdaq listing standards and SEC expectations require certain independence and audit committee composition; instances where regulators note deficiencies are disclosed in filings and may prompt remedial governance actions.
• Insider ownership and institutional stakes — Filings and market-data summaries can show concentrated insider holdings or limited institutional ownership, common in small development-stage biotechs; these patterns influence control dynamics and potential future dilution.

Exact board member names, committee composition and insider share counts should be read from the company’s most recent proxy (DEF 14A), 10-K or comparable filing for authoritative detail.

Risk factors

Investing in vrpx stock carries several material risks; the following summarizes common risk areas disclosed by the company and observable in the market:

• Clinical and development risk: The company’s programs are preclinical or early-stage; success in animal models does not guarantee human safety or efficacy.
• No approved products or commercial revenue: Virpax’s financial profile depends on financing activity rather than product sales, increasing dependency on capital markets.
• Financing and dilution risk: Additional capital raises are likely needed to advance programs, which can dilute existing shareholders.
• Liquidity and penny-stock characteristics: Low daily trading volume and low per-share prices can increase volatility and trading costs for vrpx stock.
• Listing and regulatory risk: Nasdaq deficiency letters and delisting actions materially affect market access and share liquidity.
• Execution and competition risk: Drug-delivery markets and non-opioid analgesia solutions are competitive; technical, IP or partnership setbacks can slow development.

These and other risks are described in detail in the company’s SEC risk-factor disclosures; readers should consult those legal filings before forming any view about vrpx stock.

Market performance and investor interest

vrpx stock has displayed price volatility typical of microcap biopharma equities. Public market narratives around the security have tended to include:

• Rapid intraday or multi-day percentage moves following press releases or filing updates.
• Periods of thin liquidity causing pronounced bid/ask spreads.
• Retail investor interest tied to preclinical news or speculative trading; institutional holdings historically remain limited compared with larger-cap biopharma peers.

Quantitative indicators such as short interest, historical beta and realized volatility can be found on market-data platforms (TipRanks, StockAnalysis, Tickeron) and will vary over time; given the stock’s small size, volatility metrics often exceed those of broader indices.

Recent developments (chronological highlights)

The following timeline lists recent public events affecting vrpx stock drawn from company filings and market reports. Each item includes a reported date and source attribution where available.

• March 21, 2025 — Reverse stock split executed by Virpax, changing outstanding share counts; reported in company SEC filings and summarized by market-data services (As of March 21, 2025, according to company filings).
• Early April 2025 — Nasdaq delisting notices and deficiency letters reported in market news and reflected in the company’s 8-K filings; market-data services summarized the delisting determination and company response (As of April 4, 2025, according to MarketWatch and Moomoo summaries).
• 2024–2025 period — Company announced or filed S-1 registration statements and follow-on offering documentation for equity raises; filings and press summaries list offering sizes, intended use of proceeds, and potential dilution (See company S-1 and Form S-3 filings reported throughout 2024–2025).
• 2024–2025 — Virpax reported positive preclinical outcomes for Probudur and other formulation programs in investor presentations and company updates; these results were described as supportive but remain preclinical (As reported in company materials and summarized by Seeking Alpha and StockAnalysis in early 2025).

For precise wording, dates and legal disclaimers, consult the cited SEC filings and market reports.

Investment considerations

This section presents neutral, factual items an observer or investor might monitor regarding vrpx stock; it is not investment advice.

Key drivers to watch:

• Clinical milestones: IND submissions, FDA feedback, and any first-in-human trial initiations for Probudur, Epoladerm or Envelta.
• Regulatory clearances: Any formal approvals or breakthrough designations that materially change development timelines.
• Partnerships and licensing: Strategic collaborations with larger pharmaceutical companies can provide non-dilutive capital, development expertise and validation of technology platforms.
• Cash runway and financings: Quarterly cash position and planned capital raises directly influence dilution risk and program timelines.
• Listing status: Outcomes of Nasdaq or other exchange determinations influence liquidity and market access for vrpx stock.
• Intellectual property: Patent filings and granted protections around delivery platforms can affect the company’s competitive moat.

Investors and researchers should combine these qualitative monitors with up-to-date numeric data from the company’s SEC filings and reputable market-data services.

See also

• OTC market mechanics and disclosure regimes
• Preclinical vs clinical development stages in biopharma
• Non-opioid analgesic development and drug-delivery technologies

References

The profile above synthesizes publicly available reporting and company disclosures. Key sources used for assembling this article include (select examples):

• MarketWatch market quote and news summaries for VRPX (market-data coverage and listing updates).
• Seeking Alpha company profile and SEC filing summaries (S-1, 10-Q, investor presentation excerpts).
• StockAnalysis: financials, reverse split and metrics summary for VRPX.
• Simply Wall St: company profile and listing/compliance coverage.
• Quartz: coverage of relevant SEC filings and periodic reports.
• TipRanks and Morningstar: historical prices and company overview.
• Tickeron and Moomoo: price charts, Nasdaq delisting coverage and news feeds.
• Markets.com: company overview and market-factors analysis.

As of specific reported dates referenced in this article: "As of March 21, 2025, according to company filings, Virpax executed a reverse stock split." "As of April 4, 2025, according to MarketWatch and Moomoo reporting, Nasdaq issued deficiency/delisting notices affecting Virpax’s listing status." Readers should consult the primary SEC filings (S-1, 10-Q, 8-K) for the precise, time-stamped language.

External links

• Virpax corporate website (company-provided information and press releases).
• SEC EDGAR (company S-1, 10-Q, 8-K filings for full legal text and financial tables).
• OTC Markets and market-data provider quote pages for VRPX pricing and volume history.

Important disclosures: This article is factual and educational in nature and does not constitute investment advice, a recommendation to buy or sell securities, or an endorsement of any platform. Data points such as market capitalization, trading volume, and per-share prices change over time; consult primary filings and real-time market-data services for up-to-date quantitative figures. vrpx stock is an equity in a preclinical-stage biotechnology company with the attendant risks of clinical development, financing needs, and listing compliance.

If you want to track equities or trade digital assets, consider researching regulated platforms and tools. Bitget provides an interface for digital-asset trading and wallet services; for broader market access and up-to-date data on securities like vrpx stock, refer to official company filings and established market-data providers.

To explore more company filings and latest market data on VRPX, check the issuer’s SEC filings and market-quote pages; for information on trading platforms and digital wallets, review Bitget’s product resources and educational material.